lopinavir + ritonavir + lamivudine + zidovudine + efavirenz + tenofovir disoproxil fumarate + emtricitabine

This is a multi-drug antiretroviral combination consisting of seven active pharmaceutical ingredients used in the treatment of HIV-1 infection. The components include: - **Lopinavir** (a protease inhibitor) - **Ritonavir** (a protease inhibitor, primarily used as a pharmacokinetic booster for lopinavir) - **Lamivudine** (a nucleoside reverse transcriptase inhibitor, NRTI) - **Zidovudine** (an NRTI) - **Efavirenz** (a non-nucleoside reverse transcriptase inhibitor, NNRTI) - **Tenofovir disoproxil fumarate** (an NRTI/prodrug of tenofovir) - **Emtricitabine** (an NRTI) Each drug targets different stages or enzymes in the HIV replication cycle. Lopinavir and ritonavir inhibit the viral protease enzyme, preventing maturation of infectious virus particles; ritonavir also boosts lopinavir levels by inhibiting CYP3A4 metabolism[5][7]. Lamivudine, zidovudine, tenofovir disoproxil fumarate, and emtricitabine are all nucleoside/nucleotide analogs that inhibit reverse transcriptase by causing chain termination during viral DNA synthesis[2][4]. Efavirenz is a non-nucleoside reverse transcriptase inhibitor that binds directly to reverse transcriptase and blocks its activity[2][4]. This combination would provide very broad coverage against HIV but is not available as a single fixed-dose product; rather it represents an aggregation of several standard regimens. Such combinations are typically reserved for salvage therapy or complex cases due to high pill burden and potential for overlapping toxicities and drug interactions.